Weekly FDA Roundup: Pecorino Romano Class I Recall Sweep and CGT Flexibility Shift — Week of Jan 10–17, 2026

The week of January 10–17, 2026 logged 53 FDA actions, headlined by a coordinated Class I recall sweep across a major Pecorino Romano distributor and a significant policy shift on cell and gene therapy oversight. Recalls dominated the week at 64% of all activity, while enforcement letters hit across pharma, dietary supplements, and medical devices simultaneously.

By the Numbers

• Total items: 53
• Recalls: 34 (64%) — including 8 coordinated Class I food recalls from a single distributor
• Warning letters: 7 — spanning CGMP violations in drugs, supplements, food, and devices
• Safety alerts: 7 — including two anesthesia device recalls and a major CGM correction
• Press releases: 3 — two drug/therapy milestones, one statistical methodology guidance
• Notices: 2 — clinical trial methodology and tobacco warning plans

---

Lead Story: Ambriola's Pecorino Romano Recall — Eight Brands, One Root Cause

On January 14, Ambriola Co., Inc. — a New Jersey-based Italian cheese importer and distributor — triggered eight simultaneous Class I FDA recall actions covering Pecorino Romano grated cheese products sold under multiple national retailer and branded labels. The affected products include:

• Locatelli Grated Pecorino Romano (4 oz, 8 oz, 48/8 oz, 5 lb, and 10 lb formats)
• Boar's Head Grated Pecorino Romano (6 oz cup and 5 lb bag)
• Sam's Pecorino Romano Grated (1.5 lb bag)
• Pinna Grated Pecorino Romano 2/10 (10 lb bags)
• Ambriola Piccante Grated Pecorino Romano (5 lb and 10 lb bags)

All eight actions were classified Class I — FDA's highest recall tier, reserved for situations where "there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." The FDA has not yet published the specific violation reason in the enforcement report for these items, but the coordinated nature — eight SKUs across retail, foodservice, and club store formats all traced to the same importer — points to a systemic contamination or adulteration issue at either the processing or import stage.

The practical reach is broad. Locatelli is a widely distributed retail brand found in major grocery chains nationwide. Boar's Head products move through deli counters in thousands of supermarkets. The 5 lb and 10 lb bags are foodservice formats, meaning restaurants and institutional kitchens sourcing through Ambriola would also be affected.

For food importers and co-packing operations: this recall pattern — a single source triggering cascading multi-brand Class I actions — is a textbook example of why FDA import supplier qualification programs under 21 CFR Part 117 require documented verification activities for foreign suppliers. Any distributor relabeling imported cheese products should audit their supply chain traceability now.

---

Key Developments

FDA Announces CMC Flexibility for Cell and Gene Therapies

On January 11, FDA Commissioner Marty Makary, M.D. and CBER Director Vinay Prasad, M.D. jointly announced that the agency is formalizing and broadening its flexible approach to chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies (CGTs). The announcement codifies case-by-case flexibilities that had previously been applied inconsistently, making them accessible to all CGT sponsors regardless of which CBER review team they engaged.

The core change: CGTs — which are often individualized, small-batch, and manufactured under strict time constraints — will no longer be held to the same CMC expectations as standard biologics. CBER has approved close to 50 CGTs in the past decade; this announcement is intended to accelerate the next wave by removing perceived barriers around development timelines and regulatory predictability.

For companies developing autologous cell therapies, gene editing products, or viral vector-based treatments: this is a concrete regulatory signal worth building into your development strategy and pre-IND interactions with CBER.

Abbott FreeStyle Libre 3 Medical Device Correction

On January 15, Abbott initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the U.S. The FreeStyle Libre 3 is a continuous glucose monitor (CGM) used by millions of people with diabetes. Abbott has not disclosed the specific technical issue in the safety alert summary, but corrections of this type for CGMs typically involve sensor accuracy drift, connectivity issues, or software-related misreadings.

Device corrections — as opposed to full recalls — generally do not require product return or destruction. They typically involve firmware updates, labeling changes, or user notifications. Still, any CGM inaccuracy that causes patients to dose incorrectly carries real clinical risk. Healthcare providers and patients relying on FreeStyle Libre 3 devices should monitor Abbott's direct communications for correction instructions.

Anesthesia Equipment: Two Recalls on the Same Day

January 16 brought a notable convergence of anesthesia device safety actions. Medline issued a recall of anesthesia circuits and anesthesia circuit kits, while Draeger simultaneously recalled its Vapor 2000 and Vapor 3000 anesthetic vaporizers. These are different product categories — circuits handle gas delivery to the patient; vaporizers deliver the volatile anesthetic agent — but both incidents landed on the same date, underscoring continued device quality pressures in the perioperative space.

Facilities using Medline anesthesia circuits or Draeger Vapor-series vaporizers should contact their respective distributors to determine whether their inventory is within the affected lot ranges.

Warning Letters: CGMP Sweeps Across Sectors

Seven warning letters published on January 13 touched nearly every FDA-regulated product category:

• Winder Laboratories, LLC (finished pharmaceuticals CGMP)
• Chemspec Chemicals Private Limited (API CGMP — a foreign manufacturer in the supply chain)
• LXR Biotech, LLC and Pan-African Food Distributors Inc./East Africa Boutique LLC (dietary supplement CGMP/adulterated/misbranded)
• ASP Global, LLC dba Anatomy Supply Partners, LLC (medical device CGMP/QSR)
• Middle East/Soli's Baking Company, Inc. (food CGMP/insanitary conditions)
• Purushothaman Damodara Kumaran, M.D. (bioequivalence studies — clinical investigator)

The inclusion of a clinical investigator (Dr. Kumaran) on the same week as manufacturer CGMP letters is notable. FDA is actively pursuing data integrity concerns at the clinical trial level, not just manufacturing facilities.

FDA Approves First Treatment for Menkes Disease

On January 12, FDA approved the first-ever treatment for children with Menkes disease — a rare, fatal X-linked copper metabolism disorder that typically results in severe neurological deterioration and death within the first few years of life. While the patient population is small (Menkes affects approximately 1 in 100,000 newborns), the approval is significant for the rare disease community as a signal that FDA's accelerated pathway tools are functioning for ultra-rare indications.

---

The Bigger Picture

The 34 recalls this week fit the broader pattern we track across our dataset: food products continue to dominate enforcement volume, accounting for the vast majority of recall activity. The Ambriola cluster alone represented 8 of the week's 34 recalls. Allergen-related actions — undeclared milk in VH Foods Bread Crumbs (January 12), undeclared milk in Karison Foods South Asian sweets (January 12) — are consistent with milk remaining the most-recalled allergen in FDA data, with 38 cumulative actions in our system.

The CGT CMC flexibility announcement represents the Makary FDA's clearest regulatory posture statement yet: the agency is consciously trading compliance prescriptiveness for development speed in high-innovation categories. Whether this accelerates safe products or creates gaps in manufacturing quality control will be worth watching through 2026 clinical data.

---

What to Watch

• Ambriola recall scope: Watch for follow-on actions or FDA establishment inspection updates. When an importer triggers 8 Class I recalls simultaneously, field inspections typically follow.
• Abbott FreeStyle Libre 3 correction details: The specific technical nature of the correction has not been publicly detailed. FDA's MAUDE database and Abbott's direct correction notice will contain the specifics.
• CBER CGT submissions: Sponsors who have been cautious about submitting CMC packages for cell and gene therapies should review CBER's newly published flexibility guidance and consider whether revised pre-IND strategy is warranted.
• Dietary supplement enforcement: Two dietary supplement warning letters in a single week (LXR Biotech and Pan-African Food Distributors) continues a trend of heightened attention to CGMP compliance in the supplement industry.

---

Policy Canary monitors FDA changes for your specific products — by name, by ingredient. Join the pilot program